1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to develop Artificial Intelligence (AI)-related technologies for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed) - Federal Grant Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed) The summary for the Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants. com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact .
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to develop Artificial Intelligence (AI)-related technologies for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed) National Institutes of Health (HHS-NIH11) Funding Opportunity Number: Current Application Deadline: Original Application Deadline: Maximum Federal Grant Award: Minimum Federal Grant Award: Expected Number of Awards: Cost Sharing or Matching: Applicants Eligible for this Grant Additional Information on Eligibility Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. Link to Full Grant Announcement http://grants.
nih. gov/grants/guide/rfa-files/RFA-DA-22-021. html Grant Announcement Contact If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster Similar Government Grants • Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Tr...
• Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship an... • Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional) • Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on H... • Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeu...
• NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards • Drug Abuse Aspects of Hiv/Aids and Other Infections • Epidemiology of Drug Abuse More Grants from the National Institutes of Health • Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiologi...
• Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) • Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not ... • Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) • Silvio O.
Conte Centers for Basic Neuroscience or Translational Mental Health Research (P5... Federal Grants by Category Grants for Single Mothers Small Business Grants for Women Federal Grants for College Federal Tuition Assistance
According to the current listing, eligibility includes: Small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed) is funded by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article